Literature DB >> 12781066

Limitations to the use of the CA-125 antigen level in ovarian cancer.

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12781066     DOI： 10.1007/s11912-003-0063-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  7 in total

1.  CA 125 surveillance and second-look laparotomy in ovarian carcinoma.

Authors:  D B Atack; J A Nisker; H H Allen; E R Tustanoff; L Levin
Journal:  Am J Obstet Gynecol       Date:  1986-02       Impact factor: 8.661

2.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors:  G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  The Role of CA-125 in the Management of Ovarian Cancer.

Authors: 
Journal:  Oncologist       Date:  1997

4.  Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

Authors:  J A Bridgewater; A E Nelstrop; G J Rustin; M E Gore; W P McGuire; W J Hoskins
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

5.  Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

Authors:  G J Rustin; A E Nelstrop; M K Tuxen; H E Lambert
Journal:  Ann Oncol       Date:  1996-04       Impact factor: 32.976

Review 6.  Follow-up of the asymptomatic patient with ovarian cancer.

Authors:  M Markman
Journal:  Gynecol Oncol       Date:  1994-12       Impact factor: 5.482

7.  Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.

Authors:  S C Rubin; W J Hoskins; T B Hakes; M Markman; B S Reichman; D Chapman; J L Lewis
Journal:  Am J Obstet Gynecol       Date:  1989-03       Impact factor: 8.661
  7 in total
  3 in total

Review 1.  Proteomics in cancer screening and management in gynecologic cancer.

Authors:  Wei Hu; Weiguo Wu; Ryuji Kobayashi; John J Kavanagh
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

2.  Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Authors:  Shinichi Tate; Kyoko Nishikimi; Kazuyoshi Kato; Ayumu Matsuoka; Michiyo Kambe; Takako Kiyokawa; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2019-12-09       Impact factor: 4.401

Review 3.  Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

Authors:  Michael J Evans
Journal:  Cancer Discov       Date:  2012-10-05       Impact factor: 39.397
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.